Sanofi

2024 Sanofi Biogenius Canada Grants open for applications

Retrieved on: 
Tuesday, March 19, 2024
Sanofi, Culture, Mentorship, Science, Sanofi Biogenius Canada, Education, School, Research, Gender identity, Student, Mathematics, Engineering, STEM, Creativity, Nursing

TORONTO, March 19, 2024 /CNW/ - sanofi-aventis Canada inc. (Sanofi Canada) is pleased to announce that applications for the 2024 Sanofi Biogenius Canada Grants are now open.

Key Points: 
  • TORONTO, March 19, 2024 /CNW/ - sanofi-aventis Canada inc. (Sanofi Canada) is pleased to announce that applications for the 2024 Sanofi Biogenius Canada Grants are now open.
  • The Sanofi Biogenius Canada Grants help to create equal opportunities for all students to excel in STEM fields, enabling them to build the skills required for future success.
  • The Sanofi Biogenius Canada Grants will continue to have a long-lasting impact on each school that receives these funds."
  • Public high schools across Canada can apply for the Sanofi Biogenius Canada Grants from March 15 to May 15, 2024.

Microsoft and NVIDIA announce major integrations to accelerate generative AI for enterprises everywhere

Retrieved on: 
Monday, March 18, 2024
Cloud, Microsoft, Sanofi, Microsoft Azure, GTC, Organization, Natural language processing, GPU, Triton, Broad Institute, Public health, Biotechnology, Mass General Brigham, MIT, InfiniBand, Harvard University, SAN, MIG, 3D, Microsoft Power BI, AI, University, First officer (aviation), Software, GENETICS, AUC, VM, LLM, Cloud computing, VMS, Creativity, NIM, Flywheel, NVIDIA, Health, Mass, Silicon, Video game

New NVIDIA generative AI Microservices for enterprise, developer and healthcare applications coming to Microsoft Azure AI

Key Points: 
  • New NVIDIA generative AI Microservices for enterprise, developer and healthcare applications coming to Microsoft Azure AI
    REDMOND, Wash. and SAN JOSE, Calif., March 18, 2024 /PRNewswire/ -- At GTC on Monday, Microsoft Corp. and NVIDIA expanded their longstanding collaboration with powerful new integrations that leverage the latest NVIDIA generative AI and Omniverse™ technologies across Microsoft Azure, Azure AI services, Microsoft Fabric and Microsoft 365.
  • "AI is transforming our daily lives — opening up a world of new opportunities," said Jensen Huang, founder and CEO of NVIDIA.
  • At NVIDIA GTC , Microsoft is demonstrating a preview of what is possible using Omniverse Cloud APIs on Microsoft Azure.
  • NVIDIA GPUs and NVIDIA Triton Inference Server™ help serve AI inference predictions in Microsoft Copilot for Microsoft 365.

IPG Tops the 2024 Ad Age 'A-List'

Retrieved on: 
Monday, March 11, 2024
DEI, AI, Culture, Health, Growth, The Martin Agency, Commerce, Google Chrome, PR, Advertising, Sanofi, UM, Creativity, IDI, Clinical trial, Advertising agency, IPG, Initiative, Partnership

New York, NY, March 11, 2024 (GLOBE NEWSWIRE) -- Interpublic Group (NYSE: IPG) today announced that five of its agencies were honored at the Ad Age A-List & Creativity Awards — the trade publication's coveted ranking of agencies, companies and innovators and their efforts to move the advertising industry forward, with IPG companies winning more honors than any other agency group. Recognized as top-performers in the industry, IPG Health, IPG Mediabrands, The Martin Agency, UM and The Weber Shandwick Collective were honored for their innovative and market-moving work across the advertising, media, PR and healthcare sectors.

Key Points: 
  • Recognized as top-performers in the industry, IPG Health, IPG Mediabrands, The Martin Agency, UM and The Weber Shandwick Collective were honored for their innovative and market-moving work across the advertising, media, PR and healthcare sectors.
  • 5 position on Ad Age’s 2024 Agency A-List, marking its second consecutive year on the esteemed list.
  • Since the introduction of this category last year, IPG Health remains the sole healthcare network to receive this prestigious accolade.
  • Additionally, under the leadership of Eileen Kiernan, IPG Mediabrands stood out as Ad Age's 2024 U.S. Network of the Year.

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
Monday, March 11, 2024
Therapy, Breast cancer, SAN, Pharmacology, ARIAD Pharmaceuticals, Biotechnology, Baxalta, Bone marrow, Drug development, Prostate, Acute leukemia, Acting, Stomach, Sanofi, Oxaliplatin, Astellas Pharma, Patient, Oncology, Qasr El Eyni Hospital, Stromal cell, Pancreatic cancer, IND, Head, Colorectal cancer, Cancer, Prostate cancer, Medical imaging

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers

Retrieved on: 
Wednesday, February 28, 2024
Tonix Pharmaceuticals, Toxicity, CD40L, Risk, Multiple sclerosis, Protein engineering, Thrombosis, Sanofi, Haematopoietic system, Hook effect, Kidney, Pharmaceutical industry

CHATHAM, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the completion of the clinical stage of its Phase 1, single ascending dose escalation trial of TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody, or mAb)* in healthy volunteers. TNX-1500 is in development for the prevention of rejection in solid organ and bone marrow transplant and for the treatment of autoimmune disorders.

Key Points: 
  • TNX-1500 is in development for the prevention of rejection in solid organ and bone marrow transplant and for the treatment of autoimmune disorders.
  • “Despite advancements in the field of solid organ transplantation, there remains a significant need for new treatments with improved activity and tolerability,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • “Anti-CD40L modulates T cell function and has the potential to promote tolerance of transplanted organs.
  • We are excited to have completed the clinical stage of this Phase 1 trial of TNX-1500, a third-generation Fc-modified anti-CD40L mAb that has been designed by protein engineering to eliminate the risk of thrombosis associated with first-generation anti-CD40L mAbs.

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, February 27, 2024
MPS II, Hearing, ARIA, Antibody, LRRK2, PTV, IDS, Transferrin receptor, MAPT, Traffic barrier, ALS, Hunting, Dermatan sulfate, Therapy, BBB, SAN, Total, Amyloid-related imaging abnormalities, Alpha-synuclein, COMPASS, ETV, Hunter syndrome, Neurodegenerative disease, Conference, MPS, Safety, Biomarker, OTV, LUMA, AFL, SNCA, Amyloid beta, CSF, PIPE, Glycogen storage disease, Research, ATV, FDA, Food, Risk, Sanofi, UC, CD98, Patient, Cognition, Oligonucleotide, Science, Alfa, Pharmaceutical industry

Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.

Key Points: 
  • Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
  • Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
  • There was no collaboration revenue for the quarter ended December 31, 2023, compared to $10.3 million for the quarter ended December 31, 2022.
  • Further, for the quarter ended December 31, 2023, there was also a decrease in other unallocated research and development expenses as a result of reduced facility costs.

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

Retrieved on: 
Monday, February 26, 2024
NSCLC, Acquisition, Research, Neoplasm, Investment, Melanoma, Conference, RAS, Lung cancer, Safety, Sanofi, GAAP, PDAC, Patient, Acceleration, Clinical trial, Congress, Trial of the century, Colorectal cancer, Pharmaceutical industry

“2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.

Key Points: 
  • “2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.
  • Revenue: Total revenue was $0.7 million for the quarter ended December 31, 2023, compared to $15.3 million for the quarter ended December 31, 2022.
  • Net loss for the year ended December 31, 2023, included $26.9 million of operating expenses related to the wind-down of EQRx.
  • Revolution Medicines will host a webcast this afternoon, February 26, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Retrieved on: 
Friday, February 23, 2024
AMF, File, Sanofi, Annual, Bank statement, Form

Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Key Points: 
  • Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
    Paris, February 23, 2024.
  • Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
  • These documents are available on the company’s website: https://www.sanofi.com/en/investors/reports-and-publications/financial-r...
    In addition, the Form 20-F is available on the website of the SEC ( www.sec.gov ) and the “Document d’Enregistrement Universel” is available on the website of the AMF ( www.amf-france.org ).
  • A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

AdhereTech Announces Appointment of Paul Sekhri to Board of Directors

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Senior, TPG Inc., Aidia, Teva, Integrated care, Business development, Sanofi, Chairperson, Therapy, Evaluation, Patient, Teva Pharmaceuticals, Compugen, Pharmaceutical industry

SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.

Key Points: 
  • SUMMIT, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- AdhereTech, Inc., the market leading provider of real-time medication adherence solutions proven to help patients remain on their medications longer, improving patient outcomes and pharma company revenue, today announces that long-time life sciences industry executive, Paul Sekhri, has joined the Board of Directors, effective February 7, 2024.
  • “We are excited to have Paul join the AdhereTech Board of Directors,” commented Neale Trangucci, Chair of the Board.
  • Paul Sekhri added: “I welcomed the opportunity to join the Board of AdhereTech as I see that the company’s Aidia real-time adherence technology can effectively address a major issue - non-adherence to medication.
  • I look forward to working with my fellow Board members and the management team to help ensure AdhereTech’s solutions get to those who need them.”

MEDI8897 (Nirsevimab): An Investigational Long-Acting Antibody that Protects all Infants through their First RSV Season with a Single Dose - Market Size, Forecasts, and Market Insight 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Health, Pharmaceutical, RSV, AstraZeneca, Immunization, FDA, SWOT, EU4, Nirsevimab, Sanofi, Infant, Ventricular septal defect, Disease, Research, Immune system, Pharmaceutical industry

The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.

Key Points: 
  • The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.
  • MEDI8897 (Nirsevimab) is an investigational long-acting antibody that protects all infants through their first RSV season with a single dose.
  • Nirsevimab is an immunization that provides direct prophylactic RSV protection to all infants via an antibody to help prevent LRTI caused by RSV.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MEDI8897 in RSV.